Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
Chordomas and chondrosarcomas are rare but devastating neoplasms that are characterized by chemoradiation resistance. For both tumors, surgical resection is the cornerstone of management. Immunotherapy agents are increasingly improving outcomes in multiple cancer subtypes and are being explored in c...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/10/2408 |
id |
doaj-18c8e8a143834662b47d27f707958f30 |
---|---|
record_format |
Article |
spelling |
doaj-18c8e8a143834662b47d27f707958f302021-06-01T00:12:27ZengMDPI AGCancers2072-66942021-05-01132408240810.3390/cancers13102408Immunotherapy for Chordoma and Chondrosarcoma: Current EvidenceJeffrey I. Traylor0Mark N. Pernik1Aaron R. Plitt2Michael Lim3Tomas Garzon-Muvdi4Department of Neurological Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USADepartment of Neurological Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USADepartment of Neurological Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USADepartment of Neurosurgery, Stanford University Medical Center, Stanford, CA 94305, USADepartment of Neurological Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75235, USAChordomas and chondrosarcomas are rare but devastating neoplasms that are characterized by chemoradiation resistance. For both tumors, surgical resection is the cornerstone of management. Immunotherapy agents are increasingly improving outcomes in multiple cancer subtypes and are being explored in chordoma and chondrosarcoma alike. In chordoma, brachyury has been identified as a prominent biomarker and potential molecular immunotherapy target as well as PD-1 inhibition. While studies on immunotherapy in chondrosarcoma are sparse, there is emerging evidence and ongoing clinical trials for PD-1 as well as IDH inhibitors. This review highlights potential biomarkers and targets for immunotherapy in chordoma and chondrosarcoma, as well as current clinical evidence and ongoing trials.https://www.mdpi.com/2072-6694/13/10/2408chordomachondrosarcomabrachyuryPD-1immunotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jeffrey I. Traylor Mark N. Pernik Aaron R. Plitt Michael Lim Tomas Garzon-Muvdi |
spellingShingle |
Jeffrey I. Traylor Mark N. Pernik Aaron R. Plitt Michael Lim Tomas Garzon-Muvdi Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence Cancers chordoma chondrosarcoma brachyury PD-1 immunotherapy |
author_facet |
Jeffrey I. Traylor Mark N. Pernik Aaron R. Plitt Michael Lim Tomas Garzon-Muvdi |
author_sort |
Jeffrey I. Traylor |
title |
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence |
title_short |
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence |
title_full |
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence |
title_fullStr |
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence |
title_full_unstemmed |
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence |
title_sort |
immunotherapy for chordoma and chondrosarcoma: current evidence |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-05-01 |
description |
Chordomas and chondrosarcomas are rare but devastating neoplasms that are characterized by chemoradiation resistance. For both tumors, surgical resection is the cornerstone of management. Immunotherapy agents are increasingly improving outcomes in multiple cancer subtypes and are being explored in chordoma and chondrosarcoma alike. In chordoma, brachyury has been identified as a prominent biomarker and potential molecular immunotherapy target as well as PD-1 inhibition. While studies on immunotherapy in chondrosarcoma are sparse, there is emerging evidence and ongoing clinical trials for PD-1 as well as IDH inhibitors. This review highlights potential biomarkers and targets for immunotherapy in chordoma and chondrosarcoma, as well as current clinical evidence and ongoing trials. |
topic |
chordoma chondrosarcoma brachyury PD-1 immunotherapy |
url |
https://www.mdpi.com/2072-6694/13/10/2408 |
work_keys_str_mv |
AT jeffreyitraylor immunotherapyforchordomaandchondrosarcomacurrentevidence AT marknpernik immunotherapyforchordomaandchondrosarcomacurrentevidence AT aaronrplitt immunotherapyforchordomaandchondrosarcomacurrentevidence AT michaellim immunotherapyforchordomaandchondrosarcomacurrentevidence AT tomasgarzonmuvdi immunotherapyforchordomaandchondrosarcomacurrentevidence |
_version_ |
1721415470734639104 |